The Pulmonary Fibrosis Foundation’s 2017 Summit, where pulmonary fibrosis researchers and community members from around the world can share information and experiences, will be Nov. 9-11 in Nashville, the foundation announced. Summit organizers encourage researchers, physicians, academics, industry leaders, patients and caregivers to take part in the sessions, which will highlight developments…
International Pulmonary Fibrosis Summit Scheduled for November in Nashville
This video from Big Think deals with some of the common myths surrounding depression. MORE: Did you know that pulmonary fibrosis can be difficult to diagnose and treat? Dr. Patricia Deldin from the University of Michigan Depression Center explains exactly what depression is and what it isn’t. Deldin shares that…
Antacid therapy (AAT) may lead to major digestive problems and severe lung infections in idiopathic pulmonary fibrosis (IPF) patients who take Esbriet (pirfenidone), a study reports. The research, “Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone” was published in the journal…
Boehringer Ingelheim has enrolled its first patient with progressive fibrosing interstitial lung disease (PF-ILD) in a Phase 3 clinical trial investigating the effectiveness and safety of treatment with Ofev (nintedanib). Patients with ILDs, also called diffuse parenchymal lung diseases, are often unable to breathe. The problem stems from impaired gas exchange — a consequence…
When you are diagnosed with a life-threatening illness such as pulmonary fibrosis, it is inevitable that you will feel the need to ask some big questions. Dreaded questions like “Why me?” “Why did this have to happen?” “Am I going to die?” and “How long do I…
Esbriet (pirfenidone), is an anti-fibrotic drug used in the treatment of patients with mild to moderate idiopathic pulmonary fibrosis (IPF). It’s made by the pharmaceutical company, Genentech. Find out more about Esbriet for treating idiopathic pulmonary fibrosis. A study by researchers at the University of Wisconsin found that…
ProMetic Life Sciences’s lead product for the treatment of idiopathic pulmonary fibrosis (IPF), called PBI-4050, is going to be tested in a Phase 2/3 clinical trial. Supported by efficacy data from a Phase 2 study (NCT02538536), the U.S. Food and Drug Administration (FDA) has accepted the…
When diagnosing patients with pulmonary fibrosis (PF), doctors will use a spirometry device to determine the severity of the condition. A forced vital capacity test (FVC) is needed to assess how efficiently a PF patient can breathe; patients take a deep breath and then exhale into the spirometry device for…
Bristol-Myers Squibb and Nordic Bioscience will collaborate on the development of biomarkers that can help diagnose and keep tabs on the status of fibrotic diseases like pulmonary fibrosis (PF). A biomarker is a molecule that can be used to diagnose a disease or predict its progression by…
I started noticing a change in my vision about a year ago. I’ve had the same prescription for glasses and contact lenses for 20 years. I was diagnosed with pulmonary fibrosis almost three years ago, and didn’t notice any changes in my vision for…
